Review Article | Published:

Metabolic regulation of cell growth and proliferation


Cellular metabolism is at the foundation of all biological activities. The catabolic processes that support cellular bioenergetics and survival have been well studied. By contrast, how cells alter their metabolism to support anabolic biomass accumulation is less well understood. During the commitment to cell proliferation, extensive metabolic rewiring must occur in order for cells to acquire sufficient nutrients such as glucose, amino acids, lipids and nucleotides, which are necessary to support cell growth and to deal with the redox challenges that arise from the increased metabolic activity associated with anabolic processes. Defining the mechanisms of this metabolic adaptation for cell growth and proliferation is now a major focus of research. Understanding the principles that guide anabolic metabolism may ultimately enhance ways to treat diseases that involve deregulated cell growth and proliferation, such as cancer.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    Galdieri, L., Mehrotra, S., Yu, S. & Vancura, A. Transcriptional regulation in yeast during diauxic shift and stationary phase. OMICS 14, 629–638 (2010).

  2. 2.

    Marijuan, P. C., Navarro, J. & del Moral, R. On prokaryotic intelligence: strategies for sensing the environment. Biosystems 99, 94–103 (2010).

  3. 3.

    Schaller, G. E., Shiu, S. H. & Armitage, J. P. Two-component systems and their co-option for eukaryotic signal transduction. Curr. Biol. 21, R320–R330 (2011).

  4. 4.

    DeBerardinis, R. J. et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl Acad. Sci. USA 104, 19345–19350 (2007).

  5. 5.

    Rheinwald, J. G. & Green, H. Epidermal growth factor and the multiplication of cultured human epidermal keratinocytes. Nature 265, 421–424 (1977).

  6. 6.

    Martin, P. Wound healing—aiming for perfect skin regeneration. Science 276, 75–81 (1997).

  7. 7.

    Nissen, N. N. et al. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am. J. Pathol. 152, 1445–1452 (1998).

  8. 8.

    Saltiel, A. R. & Kahn, C. R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414, 799–806 (2001).

  9. 9.

    Frauwirth, K. A. et al. The CD28 signaling pathway regulates glucose metabolism. Immunity 16, 769–777 (2002).

  10. 10.

    Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A. & Bluestone, J. A. CD28 costimulation: from mechanism to therapy. Immunity 44, 973–988 (2016).

  11. 11.

    Barthel, A. et al. Regulation of GLUT1 gene transcription by the serine/threonine kinase Akt1. J. Biol. Chem. 274, 20281–20286 (1999).

  12. 12.

    Rathmell, J. C. et al. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol. Cell. Biol. 23, 7315–7328 (2003). This work demonstrates that growth factor signalling is necessary for mammalian cells to maintain glucose uptake in support of bioenergetics and cell survival.

  13. 13.

    Wieman, H. L., Wofford, J. A. & Rathmell, J. C. Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol. Biol. Cell 18, 1437–1446 (2007).

  14. 14.

    Rathmell, J. C., Vander Heiden, M. G., Harris, M. H., Frauwirth, K. A. & Thompson, C. B. In the absence of extrinsic signals, nutrient utilization by lymphocytes is insufficient to maintain either cell size or viability. Mol. Cell 6, 683–692 (2000).

  15. 15.

    Fox, C. J., Hammerman, P. S. & Thompson, C. B. Fuel feeds function: energy metabolism and the T cell response. Nat. Rev. Immunol. 5, 844–852 (2005).

  16. 16.

    Warburg, O., Wind, F. & Negelein, E. The metabolism of tumors in the body. J. Gen. Physiol. 8, 519–530 (1927).

  17. 17.

    Warburg, O. On the origin of cancer cells. Science 123, 309–314 (1956).

  18. 18.

    Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333–339 (2013).

  19. 19.

    Recondo, G., Facchinetti, F., Olaussen, K. A., Besse, B. & Friboulet, L. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? Nat. Rev. Clin. Oncol. 15, 694–708 (2018).

  20. 20.

    Arteaga, C. L. et al. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat. Rev. Clin. Oncol. 9, 16–32 (2011).

  21. 21.

    Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).

  22. 22.

    Engelman, J. A., Luo, J. & Cantley, L. C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7, 606–619 (2006).

  23. 23.

    Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495–501 (2014).

  24. 24.

    Pavlova, N. N. & Thompson, C. B. The emerging hallmarks of cancer metabolism. Cell Metab. 23, 27–47 (2016).

  25. 25.

    Almuhaideb, A., Papathanasiou, N. & Bomanji, J. 18F-FDG PET/CT imaging in oncology. Ann. Saudi Med. 31, 3–13 (2011).

  26. 26.

    Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033 (2009).

  27. 27.

    Faubert, B. et al. Lactate metabolism in human lung tumors. Cell 171, 358–371 (2017).

  28. 28.

    Hui, S. et al. Glucose feeds the TCA cycle via circulating lactate. Nature 551, 115–118 (2017). Faubert et al. (2017) and Hui et al. (2017) provide the first evidence that lactate in the circulation can act as the major carbon source to fuel the TCA cycle in vivo.

  29. 29.

    Palm, W. & Thompson, C. B. Nutrient acquisition strategies of mammalian cells. Nature 546, 234–242 (2017).

  30. 30.

    Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. Cell 168, 960–976 (2017).

  31. 31.

    Inoki, K., Li, Y., Zhu, T., Wu, J. & Guan, K. L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4, 648–657 (2002).

  32. 32.

    Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J. & Cantley, L. C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell 10, 151–162 (2002).

  33. 33.

    Menon, S. et al. Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. Cell 156, 771–785 (2014).

  34. 34.

    Long, X., Lin, Y., Ortiz-Vega, S., Yonezawa, K. & Avruch, J. Rheb binds and regulates the mTOR kinase. Curr. Biol. 15, 702–713 (2005).

  35. 35.

    Edinger, A. L. & Thompson, C. B. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol. Biol. Cell 13, 2276–2288 (2002). This study shows that AKT promotes cell survival and growth in part by maintaining nutrient transporter levels on the plasma membrane.

  36. 36.

    Hannan, K. M. et al. mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. Mol. Cell. Biol. 23, 8862–8877 (2003).

  37. 37.

    Wolfson, R. L. & Sabatini, D. M. The dawn of the age of amino acid sensors for the mTORC1 pathway. Cell Metab. 26, 301–309 (2017).

  38. 38.

    Saxton, R. A. et al. Structural basis for leucine sensing by the Sestrin2-mTORC1 pathway. Science 351, 53–58 (2016).

  39. 39.

    Wolfson, R. L. et al. Sestrin2 is a leucine sensor for the mTORC1 pathway. Science 351, 43–48 (2016).

  40. 40.

    Chantranupong, L. et al. The CASTOR proteins are arginine sensors for the mTORC1 pathway. Cell 165, 153–164 (2016).

  41. 41.

    Gu, X. et al. SAMTOR is an S-adenosylmethionine sensor for the mTORC1 pathway. Science 358, 813–818 (2017).

  42. 42.

    Lu, P. D., Harding, H. P. & Ron, D. Translation reinitiation at alternative open reading frames regulates gene expression in an integrated stress response. J. Cell Biol. 167, 27–33 (2004).

  43. 43.

    Harding, H. P. et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol. Cell 11, 619–633 (2003).

  44. 44.

    Sato, H. et al. Transcriptional control of cystine/glutamate transporter gene by amino acid deprivation. Biochem. Biophys. Res. Commun. 325, 109–116 (2004).

  45. 45.

    Lewerenz, J. & Maher, P. Basal levels of eIF2alpha phosphorylation determine cellular antioxidant status by regulating ATF4 and xCT expression. J. Biol. Chem. 284, 1106–1115 (2009).

  46. 46.

    Lopez, A. B. et al. A feedback transcriptional mechanism controls the level of the arginine/lysine transporter cat-1 during amino acid starvation. Biochem. J. 402, 163–173 (2007).

  47. 47.

    Nicklin, P. et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 136, 521–534 (2009).

  48. 48.

    Zhang, N. et al. Increased amino acid uptake supports autophagy-deficient cell survival upon glutamine deprivation. Cell Rep. 23, 3006–3020 (2018).

  49. 49.

    Shan, J. et al. The C/ebp-Atf response element (CARE) location reveals two distinct Atf4-dependent, elongation-mediated mechanisms for transcriptional induction of aminoacyl-tRNA synthetase genes in response to amino acid limitation. Nucleic Acids Res. 44, 9719–9732 (2016).

  50. 50.

    Ye, J. et al. GCN2 sustains mTORC1 suppression upon amino acid deprivation by inducing Sestrin2. Genes Dev. 29, 2331–2336 (2015).

  51. 51.

    Siu, F., Bain, P. J., LeBlanc-Chaffin, R., Chen, H. & Kilberg, M. S. ATF4 is a mediator of the nutrient-sensing response pathway that activates the human asparagine synthetase gene. J. Biol. Chem. 277, 24120–24127 (2002).

  52. 52.

    DeNicola, G. M. et al. NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nat. Genet. 47, 1475–1481 (2015).

  53. 53.

    Locasale, J. W. et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat. Genet. 43, 869–874 (2011).

  54. 54.

    Possemato, R. et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476, 346–350 (2011). Locasale et al. (2011) and Possemato et al. (2011) provide early evidence that the serine synthesis pathway is upregulated in cancer and that it is critical in mediating tumorigenesis.

  55. 55.

    Pacold, M. E. et al. A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate. Nat. Chem. Biol. 12, 452–458 (2016).

  56. 56.

    Mullarky, E. et al. Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers. Proc. Natl Acad. Sci. USA 113, 1778–1783 (2016).

  57. 57.

    Yang, M. & Vousden, K. H. Serine and one-carbon metabolism in cancer. Nat. Rev. Cancer 16, 650–662 (2016).

  58. 58.

    Maddocks, O. D. et al. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 493, 542–546 (2013).

  59. 59.

    Maddocks, O. D. K. et al. Modulating the therapeutic response of tumours to dietary serine and glycine starvation. Nature 544, 372–376 (2017).

  60. 60.

    Lane, A. N. & Fan, T. W. Regulation of mammalian nucleotide metabolism and biosynthesis. Nucleic Acids Res. 43, 2466–2485 (2015).

  61. 61.

    Garcia-Bermudez, J. et al. Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours. Nat. Cell Biol. 20, 775–781 (2018).

  62. 62.

    Birsoy, K. et al. An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis. Cell 162, 540–551 (2015).

  63. 63.

    Sullivan, L. B. et al. Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells. Cell 162, 552–563 (2015). Birsoy et al. (2015) and Sullivan et al. (2015) demonstrate that a major function of the mitochondrial ETC is to support aspartate production.

  64. 64.

    Lauren, P. et al. Mitochondrial complex III is necessary for endothelial cell proliferation during angiogenesis. Nat. Metab. 1, 158–171 (2019).

  65. 65.

    Liu, X. et al. Regulation of mitochondrial biogenesis in erythropoiesis by mTORC1-mediated protein translation. Nat. Cell Biol. 19, 626–638 (2017).

  66. 66.

    Weinberg, S. E. et al. Mitochondrial complex III is essential for suppressive function of regulatory T cells. Nature 565, 495–499 (2019).

  67. 67.

    Alistar, A. et al. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncol. 18, 770–778 (2017).

  68. 68.

    Molina, J. R. et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat. Med. 24, 1036–1046 (2018).

  69. 69.

    Sullivan, L. B. et al. Aspartate is an endogenous metabolic limitation for tumour growth. Nat. Cell Biol. 20, 782–788 (2018).

  70. 70.

    Swanson, J. A. Shaping cups into phagosomes and macropinosomes. Nat. Rev. Mol. Cell Biol. 9, 639–649 (2008).

  71. 71.

    Recouvreux, M. V. & Commisso, C. Macropinocytosis: a metabolic adaptation to nutrient stress in cancer. Front. Endocrinol. 8, 261 (2017).

  72. 72.

    Finicle, B. T., Jayashankar, V. & Edinger, A. L. Nutrient scavenging in cancer. Nat. Rev. Cancer 18, 619–633 (2018).

  73. 73.

    Bloomfield, G. & Kay, R. R. Uses and abuses of macropinocytosis. J. Cell Sci. 129, 2697–2705 (2016).

  74. 74.

    Haigler, H. T., McKanna, J. A. & Cohen, S. Rapid stimulation of pinocytosis in human carcinoma cells A-431 by epidermal growth factor. J. Cell Biol. 83, 82–90 (1979).

  75. 75.

    Palm, W., Araki, J., King, B., DeMatteo, R. G. & Thompson, C. B. Critical role for PI3-kinase in regulating the use of proteins as an amino acid source. Proc. Natl Acad. Sci. USA 114, E8628–E8636 (2017).

  76. 76.

    Bar-Sagi, D. & Feramisco, J. R. Induction of membrane ruffling and fluid-phase pinocytosis in quiescent fibroblasts by ras proteins. Science 233, 1061–1068 (1986).

  77. 77.

    Commisso, C. et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 497, 633–637 (2013). This study shows that macropinocytosis promotes the use of extracellular protein as an amino acid source in RAS-transformed cells.

  78. 78.

    Palm, W. et al. The Utilization of Extracellular Proteins as Nutrients Is Suppressed by mTORC1. Cell 162, 259–270 (2015). This work demonstrates that mTORC1 activity suppresses the use of extracellular protein as an amino acid source through macropinocytosis.

  79. 79.

    Garcia, D. & Shaw, R. J. AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance. Mol. Cell 66, 789–800 (2017).

  80. 80.

    Kim, S. M. et al. PTEN deficiency and AMPK activation promote nutrient scavenging and anabolism in prostate cancer cells. Cancer Discov. 8, 866–883 (2018).

  81. 81.

    Nofal, M., Zhang, K., Han, S. & Rabinowitz, J. D. mTOR inhibition restores amino acid balance in cells dependent on catabolism of extracellular protein. Mol. Cell 67, 936–946 (2017).

  82. 82.

    Goldberg, I. J., Eckel, R. H. & Abumrad, N. A. Regulation of fatty acid uptake into tissues: lipoprotein lipase- and CD36-mediated pathways. J. Lipid Res. 50, S86–S90 (2009).

  83. 83.

    Menendez, J. A. & Lupu, R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 7, 763–777 (2007).

  84. 84.

    Zaidi, N. et al. Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog. Lipid Res. 52, 585–589 (2013).

  85. 85.

    Medes, G., Thomas, A. & Weinhouse, S. Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res. 13, 27–29 (1953).

  86. 86.

    Gansler, T. S., Hardman, W. 3rd, Hunt, D. A., Schaffel, S. & Hennigar, R. A. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum. Pathol. 28, 686–692 (1997).

  87. 87.

    Sebastiani, V. et al. Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma. Gynecol. Oncol. 92, 101–105 (2004).

  88. 88.

    Visca, P. et al. Fatty acid synthase (FAS) is a marker of increased risk of recurrence in lung carcinoma. Anticancer Res. 24, 4169–4173 (2004).

  89. 89.

    Mashima, T., Seimiya, H. & Tsuruo, T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br. J. Cancer 100, 1369–1372 (2009).

  90. 90.

    Pascual, G. et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature 541, 41–45 (2017).

  91. 91.

    Zhang, M. et al. Adipocyte-derived lipids mediate melanoma progression via FATP proteins. Cancer Discov. 8, 1006–1025 (2018).

  92. 92.

    Sounni, N. E. et al. Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal. Cell Metab. 20, 280–294 (2014).

  93. 93.

    Hochachka, P. W., Rupert, J. L., Goldenberg, L., Gleave, M. & Kozlowski, P. Going malignant: the hypoxia-cancer connection in the prostate. Bioessays 24, 749–757 (2002).

  94. 94.

    Ackerman, D. & Simon, M. C. Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment. Trends Cell Biol. 24, 472–478 (2014).

  95. 95.

    Zhang, Z., Dales, N. A. & Winther, M. D. Opportunities and challenges in developing stearoyl-coenzyme A desaturase-1 inhibitors as novel therapeutics for human disease. J. Med. Chem. 57, 5039–5056 (2014).

  96. 96.

    Igal, R. A. Stearoyl CoA desaturase-1: new insights into a central regulator of cancer metabolism. Biochim. Biophys. Acta 1861, 1865–1880 (2016).

  97. 97.

    Kamphorst, J. J. et al. Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc. Natl Acad. Sci. USA 110, 8882–8887 (2013).

  98. 98.

    Ackerman, D. et al. Triglycerides promote lipid homeostasis during hypoxic stress by balancing fatty acid saturation. Cell Rep. 24, 2596–2605 (2018).

  99. 99.

    Vriens, K. et al. Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity. Nature 566, 403–406 (2019).

  100. 100.

    Nosal, J. M., Switzer, R. L. & Becker, M. A. Overexpression, purification, and characterization of recombinant human 5-phosphoribosyl-1-pyrophosphate synthetase isozymes I and II. J. Biol. Chem. 268, 10168–10175 (1993).

  101. 101.

    Qian, X. et al. Conversion of PRPS hexamer to monomer by AMPK-mediated phosphorylation inhibits nucleotide synthesis in response to energy stress. Cancer Discov. 8, 94–107 (2018).

  102. 102.

    Graves, L. M. et al. Regulation of carbamoyl phosphate synthetase by MAP kinase. Nature 403, 328–332 (2000).

  103. 103.

    Sigoillot, F. D. et al. Nuclear localization and mitogen-activated protein kinase phosphorylation of the multifunctional protein CAD. J. Biol. Chem. 280, 25611–25620 (2005).

  104. 104.

    Ben-Sahra, I., Howell, J. J., Asara, J. M. & Manning, B. D. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science 339, 1323–1328 (2013).

  105. 105.

    Robitaille, A. M. et al. Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science 339, 1320–1323 (2013).

  106. 106.

    Wang, Y. & Hekimi, S. Understanding ubiquinone. Trends Cell Biol. 26, 367–378 (2016).

  107. 107.

    White, R. M. et al. DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature 471, 518–522 (2011).

  108. 108.

    Sykes, D. B. et al. Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia. Cell 167, 171–186 (2016).

  109. 109.

    Ducker, G. S. & Rabinowitz, J. D. One-carbon metabolism in health and disease. Cell Metab. 25, 27–42 (2017).

  110. 110.

    Ben-Sahra, I., Hoxhaj, G., Ricoult, S. J. H., Asara, J. M. & Manning, B. D. mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle. Science 351, 728–733 (2016).

  111. 111.

    Shi, Y., Evans, J. E. & Rock, K. L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425, 516–521 (2003).

  112. 112.

    Boeynaems, J. M. & Communi, D. Modulation of inflammation by extracellular nucleotides. J. Invest. Dermatol. 126, 943–944 (2006).

  113. 113.

    Scheibner, K. A. et al. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J. Immunol. 177, 1272–1281 (2006).

  114. 114.

    Singer, A. J. & Clark, R. A. Cutaneous wound healing. N. Engl. J. Med. 341, 738–746 (1999).

  115. 115.

    Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16, 582–598 (2016).

  116. 116.

    Dvorak, H. F. Tumors: wounds that do not heal-redux. Cancer Immunol. Res. 3, 1–11 (2015).

  117. 117.

    Sullivan, W. J. et al. Extracellular matrix remodeling regulates glucose metabolism through TXNIP destabilization. Cell 175, 117–132 (2018).

  118. 118.

    Camps, J. L. et al. Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc. Natl Acad. Sci. USA 87, 75–79 (1990).

  119. 119.

    Olumi, A. F. et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59, 5002–5011 (1999).

  120. 120.

    Curtis, M. et al. Fibroblasts mobilize tumor cell glycogen to promote proliferation and metastasis. Cell Metab. 29, 141–155 (2018).

  121. 121.

    Keith, B. & Simon, M. C. Hypoxia-inducible factors, stem cells, and cancer. Cell 129, 465–472 (2007).

  122. 122.

    Trabold, O. et al. Lactate and oxygen constitute a fundamental regulatory mechanism in wound healing. Wound Repair Regen. 11, 504–509 (2003).

  123. 123.

    Kamphorst, J. J. et al. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res. 75, 544–553 (2015).

  124. 124.

    Pan, M. et al. Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation. Nat. Cell Biol. 18, 1090–1101 (2016).

  125. 125.

    Muranen, T. et al. Starved epithelial cells uptake extracellular matrix for survival. Nat. Commun. 8, 13989 (2017).

  126. 126.

    Olivares, O. et al. Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions. Nat. Commun. 8, 16031 (2017).

  127. 127.

    Katheder, N. S. & Rusten, T. E. Microenvironment and tumors-a nurturing relationship. Autophagy 13, 1241–1243 (2017).

  128. 128.

    Sousa, C. M. et al. Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature 536, 479–483 (2016). This work shows that autophagic degradation and release of cellular constituents in pancreatic stellate cells can support the growth of pancreatic cancer cells.

  129. 129.

    Nieman, K. M. et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 17, 1498–1503 (2011).

  130. 130.

    Rabinowitz, J. D. & White, E. Autophagy and metabolism. Science 330, 1344–1348 (2010).

  131. 131.

    Kaur, J. & Debnath, J. Autophagy at the crossroads of catabolism and anabolism. Nat. Rev. Mol. Cell Biol. 16, 461–472 (2015).

  132. 132.

    Wyant, G. A. et al. NUFIP1 is a ribosome receptor for starvation-induced ribophagy. Science 360, 751–758 (2018).

  133. 133.

    Amaravadi, R., Kimmelman, A. C. & White, E. Recent insights into the function of autophagy in cancer. Genes Dev. 30, 1913–1930 (2016).

  134. 134.

    Karsli-Uzunbas, G. et al. Autophagy is required for glucose homeostasis and lung tumor maintenance. Cancer Discov. 4, 914–927 (2014).

  135. 135.

    Guo, J. Y. et al. Autophagy provides metabolic substrates to maintain energy charge and nucleotide pools in Ras-driven lung cancer cells. Genes Dev. 30, 1704–1717 (2016).

  136. 136.

    Yang, S. et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 25, 717–729 (2011).

  137. 137.

    Yang, A. et al. Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. Cancer Discov. 4, 905–913 (2014).

  138. 138.

    Yang, A. et al. Autophagy sustains pancreatic cancer growth through both cell-autonomous and nonautonomous mechanisms. Cancer Discov. 8, 276–287 (2018).

  139. 139.

    Poillet-Perez, L. et al. Autophagy maintains tumour growth through circulating arginine. Nature 563, 569–573 (2018).

  140. 140.

    Allen, E. L. et al. Differential aspartate usage identifies a subset of cancer cells particularly dependent on OGDH. Cell Rep. 17, 876–890 (2016).

  141. 141.

    Ilic, N. et al. PIK3CA mutant tumors depend on oxoglutarate dehydrogenase. Proc. Natl Acad. Sci. USA 114, E3434–E3443 (2017).

  142. 142.

    Ye, J. et al. Serine catabolism regulates mitochondrial redox control during hypoxia. Cancer Discov. 4, 1406–1417 (2014).

  143. 143.

    Muir, A. et al. Environmental cystine drives glutamine anaplerosis and sensitizes cancer cells to glutaminase inhibition. eLife 6, e27713 (2017).

  144. 144.

    Shin, C. S. et al. The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility. Nat. Commun. 8, 15074 (2017).

  145. 145.

    Kong, H. & Chandel, N. S. Regulation of redox balance in cancer and T cells. J. Biol. Chem. 293, 7499–7507 (2018).

  146. 146.

    Tonks, N. K. Redox redux: revisiting PTPs and the control of cell signaling. Cell 121, 667–670 (2005).

  147. 147.

    Tormos, K. V. et al. Mitochondrial complex III ROS regulate adipocyte differentiation. Cell Metab. 14, 537–544 (2011).

  148. 148.

    Weinberg, F. et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl Acad. Sci. USA 107, 8788–8793 (2010).

  149. 149.

    Schafer, Z. T. et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461, 109–113 (2009).

  150. 150.

    DeNicola, G. M. et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475, 106–109 (2011).

  151. 151.

    Harris, I. S. et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell 27, 211–222 (2015).

  152. 152.

    Piskounova, E. et al. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature 527, 186–191 (2015). This work demonstrates that melanoma cells need to overcome the oxidative stress barrier in order to successfully metastasize.

  153. 153.

    Luengo, A., Gui, D. Y. & Vander Heiden, M. G. Targeting metabolism for cancer therapy. Cell Chem. Biol. 24, 1161–1180 (2017).

  154. 154.

    Parker, W. B. Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. Chem. Rev. 109, 2880–2893 (2009).

  155. 155.

    Cantley, L. C. The phosphoinositide 3-kinase pathway. Science 296, 1655–1657 (2002).

  156. 156.

    Manning, B. D. & Cantley, L. C. AKT/PKB signaling: navigating downstream. Cell 129, 1261–1274 (2007).

  157. 157.

    Manning, B. D. & Toker, A. AKT/PKB signaling: navigating the network. Cell 169, 381–405 (2017).

  158. 158.

    Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2, 489–501 (2002).

Download references


The authors thank members of the Thompson laboratory for critical discussions during manuscript preparation. J.Z. is supported by the Leukemia and Lymphoma Society postdoctoral fellowship.

Reviewer information

Nature Reviews Molecular Cell Biology thanks N. Chandel, D. Sabatini, and other anonymous reviewer(s), for their contribution to the peer review of this work.

Author information

The authors contributed equally to all aspects of the article.

Competing interests

C.B.T. is a founder of Agios Pharmaceuticals and a member of its scientific advisory board. He is also a former member of the Board of Directors and stockholder of Merck and Charles River Laboratories. He has patents related to cellular metabolism.

Correspondence to Craig B. Thompson.

Supplementary information

Supplementary Box 1


Non-essential amino acids

(NEAAs). Amino acids that can be synthesized endogenously and often participate in processes beyond protein translation, such as nucleotide synthesis.


The set of biochemical reactions that replenish the intermediates of metabolic pathways.

Minimal medium

Medium that contains the minimum nutrients possible for the growth of cells.

Positron-emission-tomography-based imaging

An imaging technique used clinically to observe metabolic processes for disease diagnosis or monitoring.

p70S6 kinase 1

(S6K1). A kinase downstream of the mTOR complex 1 signalling pathway, the activation of which can lead to increased protein synthesis.

eIF4E binding protein 1

(4EBP1). A protein translation repressor. Its activity is inhibited by phosphorylation mediated by mTOR complex 1 to increase protein synthesis.

Integrated stress response

A mechanism that usually suppresses general protein synthesis but promotes the expression of specific transcription factors to mediate cellular stress response.

Alternative open reading frames

Different open reading frames within a gene, the transcription of which can lead to different gene products that may assume different biological roles.


The oxidized dimer form of the amino acid cysteine.

Endoplasmic reticulum (ER) stress

Cellular stress in the ER that often results from the accumulation of misfolded proteins or a failure to maintain the membrane integrity of the ER.


Derivatives of phospholipids in which one of the two acyl chains is lost.


A fatty acid that is usually a component of the secretion from sebaceous glands in the skin. Sapienate can be synthesized from palmitate by desaturation.

Pentose phosphate pathway

A metabolic pathway parallel to glycolysis that involves the generation of various pentoses including ribose 5-phosphate that functions as a precursor for nucleotide synthesis.

One-carbon-unit cycle

A group of biochemical reactions that involve the transfer of the one-carbon groups between various molecules such as tetrahydrofolate, S-adenosylmethionine and vitamin B12.


A coenzyme that functions as an electron carrier in various biological processes, including the electron transport chain as part of aerobic cellular respiration.

Folate cycle

A group of biochemical reactions occurring in both the cytosolic and mitochondrial compartments that involve the metabolism of folate and its congeners. The folate cycle can provide critical metabolic intermediates for the biosynthesis of macromolecules such as nucleotides.


A chemical used in cancer treatment that often interferes with cellular nucleotide synthesis and DNA replication.


A medication used in cancer treatment primarily by targeting the thymidylate synthase to block thymidine synthesis.

Damage-associated molecular patterns

A group of biomolecules that are enriched upon non-infectious inflammatory responses such as during the process of wound healing.


A class of small proteins encoded by the TXN and TXN2 genes that mainly function as cellular antioxidants.

Cancer-associated fibroblasts

(CAFs). Cells derived from normal fibroblasts within the tumour microenvironment that promote cancer development.


Layers of peritoneum that surround abdominal organs.

Malate–aspartate shuttle

A biochemical system that translocates electrons from the cytosol into the mitochondria for oxidative phosphorylation; the process involves the exchange of malate and aspartate between the two compartments.


A tripeptide of glutamate, cysteine and glycine that, together with glutathione-utilizing enzymes, functions to maintain cellular redox homeostasis and to detoxify electrophilic compounds such as reactive oxygen species.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1: Glucose uptake and utilization.
Fig. 2: Amino acid sensing and acquisition.
Fig. 3: Fatty acid synthesis.
Fig. 4: Synthesis of pyrimidine and purine nucleotides.
Fig. 5: Metabolic interactions with the extracellular environment.
Fig. 6: Maintaining redox homeostasis in proliferating cells.